Market Exclusive

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) gets upgraded to Outperform by Leerink Swann

Analyst Ratings For ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)

Today, ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) stock received an upgrade by Leerink Swann from Market Perform to Outperform.

There are 9 Buy Ratings, 2 Hold Ratings, 1 Strong Buy Ratings, no Sell Ratings on the stock.

The current consensus rating on ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) is Buy with a consensus target price of $44.75 per share, a potential 14.33% upside.

Some recent analyst ratings include

Recent Trading Activity for ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)
Shares of ACADIA Pharmaceuticals Inc. closed the previous trading session at 39.14 −2.25 5.44% with 39.05 shares trading hands.

Exit mobile version